• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, May 20, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncotarget: Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

Bioengineer by Bioengineer
June 28, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Support recently reported findings of clinical benefit when relacorilant is added to paclitaxel-containing therapy in patients with ovarian and pancreatic cancers and provide a new rationale for combining relacorilant with additional cytotoxic agents

IMAGE

Credit: Correspondence to – Andrew E. Greenstein – [email protected]

Oncotarget published “Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells” which reported that to guide studies in cancer patients, relacorilant, an investigational selective GR modulator that antagonizes cortisol activity, was assessed in various tumor types, with multiple cytotoxic combination partners, and in the presence of physiological cortisol concentrations.

In the MIA PaCa-2 cell line, paclitaxel-driven apoptosis was blunted by cortisol and restored by relacorilant.

A screen to identify optimal combination partners for relacorilant showed that microtubule-targeted agents consistently benefited from combination with relacorilant.

These findings were confirmed in xenograft models, including MIA PaCa-2, HeLa, and a cholangiocarcinoma patient-derived xenograft. In vivo, tumor-cell apoptosis was increased when relacorilant was added to paclitaxel in multiple models.

These observations support recently reported findings of clinical benefit when relacorilant is added to paclitaxel-containing therapy in patients with ovarian and pancreatic cancers and provide a new rationale for combining relacorilant with additional cytotoxic agents.

Support recently reported findings of clinical benefit when relacorilant is added to paclitaxel-containing therapy in patients with ovarian and pancreatic cancers and provide a new rationale for combining relacorilant with additional cytotoxic agents.

Dr. Andrew E. Greenstein from Corcept Therapeutics said, “Drug resistance, whether primary or acquired, is a major impediment to cancer therapy.“

GR agonism could contribute to tumor cell biology even in patients with normal cortisol levels.

GR agonists, including cortisol, have demonstrated pro-apoptotic effects in hematological malignancies, cytostatic effects on sarcoma-derived cell lines, and anti-apoptotic effects in carcinoma cell lines.

Unlike the non-specific steroidal GR antagonist mifepristone, relacorilant does not exhibit partial agonist activity toward human or mouse GR.

Mifepristone and relacorilant are both competitive antagonists of the GR and are best studied in the context of physiologically relevant cortisol concentrations.

In a phase 2 study in patients with Cushing syndrome, relacorilant demonstrated the ability to reverse the effects of excess cortisol on hypertension and insulin resistance, and it is currently being studied in two phase 3 trials in patients with endogenous Cushing syndrome, GRACE and GRADIENT.

The Greenstein Research Team concluded in their Oncotarget Research Output that the initial in vitro observations suggested that an increase in apoptosis, rather than a decrease in proliferation rate, was achieved when relacorilant was added to a cytotoxic therapy.

To determine if this was recapitulated in vivo, apoptosis markers were assessed in relacorilant-treated xenografts.

The CC6279 cholangiocarcinoma model was assessed because the relacorilant effect size was greatest. Cleaved caspase 3 activity was qualitatively and quantitatively elevated in mice treated with relacorilant paclitaxel compared to paclitaxel alone, while no difference was observed for CK18 and Ki67.

Consistent with the initial in vitro observation, relacorilant promoted tumor cell apoptosis in xenograft models.

###

DOI – https://doi.org/10.18632/oncotarget.27989

Full text – https://www.oncotarget.com/article/27989/text/

Correspondence to – Andrew E. Greenstein – [email protected]

Keywords –
glucocorticoid,
tumors,
apoptosis,
chemotherapy,
drug resistance

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
RYAN JAMES JESSUP
[email protected]

Original Source

https://www.oncotarget.com/news/pr/glucocorticoid-receptor-antagonism-promotes-apoptosis-in-solid-tumor-cells/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27989

Tags: BiologyBusiness/EconomicscancerCarcinogensEducationMedicine/HealthPolicy/Ethics
Share12Tweet8Share2ShareShareShare2

Related Posts

A new method to reduce deadly hospital infections

Scientists devise method to prevent deadly hospital infections without antibiotics

May 19, 2022
Some people fared better than others during COVID-19 pandemic due to genetics

Some people fared better than others during COVID-19 pandemic due to genetics

May 19, 2022

Genetic risk scores help predict type 2 diabetes in people of south Asian origin, study finds

May 19, 2022

Repurposed antibiotic may be an effective therapeutic in COVID-19 infected mice

May 19, 2022
Please login to join discussion

POPULAR NEWS

  • Weybourne Atmospheric Observatory

    Breakthrough in estimating fossil fuel CO2 emissions

    46 shares
    Share 18 Tweet 12
  • Hidden benefit: Facemasks may reduce severity of COVID-19 and pressure on health systems, researchers find

    44 shares
    Share 18 Tweet 11
  • Discovery of the one-way superconductor, thought to be impossible

    43 shares
    Share 17 Tweet 11
  • Sweet discovery could drive down inflammation, cancers and viruses

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

University of WashingtonZoology/Veterinary ScienceWeaponryVehiclesWeather/StormsViolence/CriminalsVaccineVirusVaccinesUrogenital SystemVirologyUrbanization

Recent Posts

  • ‘Moth motorways’ could help resist climate change impact
  • Satellites and drones can help save pollinators
  • What the new Jurassic Park movie gets wrong: Aerodynamic analysis causes a rethink of the biggest pterosaur.
  • Biocompatible binary hologram with drug-elution capabilities
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....